Atypical hemolytic-uremic syndrome 3

Common Name(s)

Atypical hemolytic-uremic syndrome 3

Atypical hemolytic uremic syndrome 3 (aHUS 3) is a rare genetic disease in which red blood cells are abnormally destroyed, leading to a decreased red blood cell count (anemia) and destruction of the platelets (thrombocytopenia). Platelets are found circulating in the blood and are involved in clot formation to stop bleeding. aHUS 3 is a chronic and often progressive condition. This particular type of aHUS is caused by a mutation or change in the CFI gene. This gene is responsible for making proteins that help regulate the complement system, which is a part of the immune system that helps to get rid of things that may be harmful to the body.

Early symptoms of aHUS 3 include malaise, tiredness, lethargy, and irritability. Later, individuals usually develop swelling, blood in the urine, protein in the urine, and a reduced amount of albumin in the blood. Albumin is a major protein in blood that helps to regulate blood pressure and transport proteins and other substances. The debris from destroyed red blood cells in aHUS 3 can clog or damage the tiny blood vessels in the kidney, which is the organ that filters blood and produces urine. Kidney failure may occur and is a feared complication of this condition.

aHUS 3 is often diagnosed based on family history, genetic testing, and signs of a low red blood cell count (anemia), a low platelet count (thrombocytopenia), and kidney damage. Treatment may include IV fluid and nutrient replacement, blood transfusions, and medication to help maintain blood pressure. If the kidneys stop working, then dialysis may be needed in order to filter the blood. If you or a loved one has been diagnosed with aHUS 3, talk to your doctor about the most current treatment options. In addition, a genetic counselor can help discuss inheritance and risks to other family members.

Source: Advocacy organizations associated with the condition.

 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Atypical hemolytic-uremic syndrome 3" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Atypical hemolytic-uremic syndrome 3" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Atypical hemolytic-uremic syndrome 3" returned 1 free, full-text research articles on human participants. First 3 results:

Atypical hemolytic uremic syndrome-associated variants and autoantibodies impair binding of factor h and factor h-related protein 1 to pentraxin 3.
 

Author(s): Anne Kopp, Stefanie Strobel, Agustín Tortajada, Santiago Rodríguez de Córdoba, Pilar Sánchez-Corral, Zoltán Prohászka, Margarita López-Trascasa, Mihály Józsi

Journal: J. Immunol.. 2012 Aug;189(4):1858-67.

 

Atypical hemolytic uremic syndrome (aHUS) is a renal disease associated with complement alternative pathway dysregulation and is characterized by endothelial injury. Pentraxin 3 (PTX3) is a soluble pattern recognition molecule expressed by endothelial cells and upregulated under inflammatory ...

Last Updated: 3 Aug 2012

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Atypical hemolytic-uremic syndrome 3" returned 0 free, full-text review articles on human participants.

 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in Genetics Home Reference.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

There are currently no open clinical trials for this condition.